Krieger J, Mangin P, Kurtz D
Rev Electroencephalogr Neurophysiol Clin. 1979 Jul-Sep;9(3):250-7. doi: 10.1016/s0370-4475(79)80006-4.
Beneficial effects have been attributed to Chlorimipramine in the treatment of sleep apnea syndrome (SAS). However, there were no quantitative evaluations of these effects. Polygraphic studies were made before and after chlorimipramine treatment (75 mg per day for 3 to 16 months). The 3 SAS subjects, whose weight remained stable throughout the course of treatment, showed no evidence of reduced hypopnea and apnea during sleep.
氯米帕明在治疗睡眠呼吸暂停综合征（SAS）方面具有有益作用。然而，尚未对这些作用进行定量评估。在氯米帕明治疗前后（每天75毫克，持续3至16个月）进行了多导睡眠图研究。3名SAS受试者在整个治疗过程中体重保持稳定，但睡眠期间未显示出呼吸浅慢和呼吸暂停减少的迹象。
